BOSTON--(BUSINESS WIRE)--

EvaluatePharma, the premier source for pharmaceutical and biotechnology sector analysis and consensus forecasts, today released a report, titled Surveying Tomorrows BioPharma Landscape: The NASDAQ Biotech Index Up Close, which shows that the quantity of biologic drugs on the market will likely soar by 2018. A thorough analysis of companies listed on the NASDAQ Biotechnology Index (NBI) revealed that while less than 10 percent of these companies currently marketed products are biologic drugs pharmaceuticals derived from living organisms these products comprise a hefty 40 percent of the companies drug pipelines. [Note to editors: The report is available for download at http://www.evaluatepharma.com/NBI2012.%5D

The EvaluatePharma report also reveals the diversity of the 117 companies listed on the index, with insights about pipeline development and consensus sales estimates. The analysis points to a growing focus on biologics, including drugs treating cancer, infection and central nervous system diseases.

EvaluatePharma the first company to provide reliable consensus forecasts of global drug sales developed the report to give investors and the life science community at large a better understanding of the products and trends driving the index.

The NASDAQ Biotech Index is cited all around the world, but rarely do we see a detailed aggregate analysis of these leading, publicly traded biotechnology companies. This analysis provides insight into the breadth and scope of todays products and looks at where this dynamic sector is heading.

Among the reports key takeaways:

Access the complete report online. A PDF version is available at http://www.evaluatepharma.com/NBI2012.

About EvaluatePharma

Since 1996, EvaluatePharma has been the premier source for pharmaceutical and biotechnology sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of 75 dedicated healthcare analysts employing rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharmas analysis, and enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.evaluatepharma.com.

Read more here:
EvaluatePharma Analysis Provides Insight on Tomorrow’s BioPharma Landscape with Close-Up Look at NASDAQ Biotech Index